JP2021512161A5 - - Google Patents

Info

Publication number
JP2021512161A5
JP2021512161A5 JP2020562086A JP2020562086A JP2021512161A5 JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5 JP 2020562086 A JP2020562086 A JP 2020562086A JP 2020562086 A JP2020562086 A JP 2020562086A JP 2021512161 A5 JP2021512161 A5 JP 2021512161A5
Authority
JP
Japan
Prior art keywords
hydrogen
pharmaceutically acceptable
solvate
compound according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020562086A
Other languages
English (en)
Japanese (ja)
Other versions
JP7337395B2 (ja
JP2021512161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015547 external-priority patent/WO2019148161A1/en
Publication of JP2021512161A publication Critical patent/JP2021512161A/ja
Publication of JP2021512161A5 publication Critical patent/JP2021512161A5/ja
Application granted granted Critical
Publication of JP7337395B2 publication Critical patent/JP7337395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020562086A 2018-01-29 2019-01-29 Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用 Active JP7337395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623516P 2018-01-29 2018-01-29
US62/623,516 2018-01-29
PCT/US2019/015547 WO2019148161A1 (en) 2018-01-29 2019-01-29 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2021512161A JP2021512161A (ja) 2021-05-13
JP2021512161A5 true JP2021512161A5 (https=) 2022-01-17
JP7337395B2 JP7337395B2 (ja) 2023-09-04

Family

ID=67394794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562086A Active JP7337395B2 (ja) 2018-01-29 2019-01-29 Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用

Country Status (15)

Country Link
US (1) US11352341B2 (https=)
EP (1) EP3746072B1 (https=)
JP (1) JP7337395B2 (https=)
KR (1) KR20200115583A (https=)
CN (1) CN111989099A (https=)
AU (1) AU2019211491B2 (https=)
BR (1) BR112020015405A2 (https=)
CA (1) CA3088381A1 (https=)
EA (1) EA202091450A1 (https=)
IL (1) IL275948A (https=)
MX (1) MX2020007959A (https=)
PH (1) PH12020551155A1 (https=)
SG (1) SG11202006748RA (https=)
TW (1) TW201940166A (https=)
WO (1) WO2019148161A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
MX2020013808A (es) * 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
MA55909A (fr) * 2019-05-05 2022-03-16 Qilu Regor Therapeutics Inc Inhibiteurs de cdk
US12570633B2 (en) 2020-06-22 2026-03-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Preparation method for CDK4/6 inhibitor
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
AU2004255934B2 (en) 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US9796701B2 (en) * 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
CA2954298A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN111333627B (zh) * 2015-03-11 2024-09-13 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
CN107286134B (zh) * 2016-04-11 2019-04-12 上海勋和医药科技有限公司 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用

Similar Documents

Publication Publication Date Title
JP2021512161A5 (https=)
CN115803326A (zh) Egfr抑制剂及其制备方法与在药学上的应用
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
JP2020500862A5 (https=)
JP2023525656A (ja) Ｅｇｆｒ阻害剤、その調製方法及びその使用
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2018517686A5 (https=)
JP2020531447A5 (https=)
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
JP2018536634A5 (https=)
JP2018516917A5 (https=)
JP2021512087A5 (https=)
CN109803972A (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
JP2005516067A5 (https=)
CN102395576A (zh) 调控jak激酶的喹唑啉衍生物和其使用方法
JP2009513703A5 (https=)
JP2018526376A5 (https=)
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2015508103A5 (https=)
JP2005525322A5 (https=)
JP2022553954A5 (https=)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2023509944A5 (https=)
CN117062819A (zh) 多环化合物及其用途